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ABSTRACT 
Neurokinin B (NKB) is a potential regulator of pulsatile gonadotropin-releasing hormone (GnRH) 
secretion via activation of the neurokinin-3 receptor (NK3R). NKB with the consensus sequence of 
the tachykinin peptide family also binds to other tachykinin receptors [neurokinin-1 receptor (NK1R) 
and neurokinin-2 receptor (NK2R)] with low selectivity. In order to identify the structural 
requirements for the development of novel potent and selective NK3R agonists, a structure-activity 
relationship (SAR) study of [MePhe7]-NKB and other naturally occurring tachykinin peptides was 
performed. The substitutions to naturally occurring tachykinins with Asp and MePhe improved the 
receptor binding and agonistic activity for NK3R. The corresponding substitutions to NKB provided 
an NK3R selective analog.  
 
KEYWORDS 
neurokinin B, [MePhe7]-neurokinin B, NK3R, tachykinin, GnRH 
 
Abbreviations: GnRH, gonadotropin-releasing hormone; ARC, arcuate nucleus; NK1R, neurokinin-1 
receptor; NK2R, neurokinin-2 receptor; NK3R, neurokinin-3 receptor; LH, Luteinizing hormone; SP, 
substance P; BH-SP, Bolton-Hunter labeled substance P; NKA, neurokinin A, NKB, neurokinin B; 
Dyn, dynorphin A; Nle, norleucine; MePhe, N-methylphenylalanine. 
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1. Introduction 
Pulsatile release of gonadotropin-releasing hormone (GnRH) is a prerequisite for reproductive 
success in mammals.1,2 Pulsatile GnRH secretion has been suggested to be regulated by potential 
“GnRH pulse generator(s)”, which locate at the arcuate nucleus (ARC) in the hypothalamus;3 
however, the precise cellular and molecular mechanism to generate the rhythmic discharge of GnRH 
has not been revealed. One of the stimulatory regulators for the GnRH neuronal network is 
kisspeptin,4 encoded by the Kiss1 gene.5 Kisspeptins and the related peptides promote GnRH 
secretion via activation of the corresponding receptor GPR54.6,7 In ARC, kisspeptin neurons provide 
a tonic drive to GnRH neurons via transsynaptic inputs.8 The administration of kisspeptins or related 
peptides9,10 effectively induces ovulation by a transient increase in GnRH/LH secretion (a GnRH 
surge).11,12 In addition, the peripheral administration of kisspeptin-10, which is a potent GPR54 
agonist, elicits a robust LH release in goat and rat without any effect on the GnRH pulse.13,14 These 
observations suggest that kisspeptins are unlikely to be involved in the regulation of pulsatile GnRH 
secretion. 
Recently, it has been reported that kisspeptin-containing neurons coexpress neurokinin B (NKB) 
and dynorphin A (Dyn).15-17 Central administration of NKB immediately induces pulsatile GnRH 
secretion, suggesting that NKB and its cognate receptor, the neurokinin-3 receptor (NK3R), are 
involved in generating GnRH pulses.17 Indeed, it has been reported that a mutation in either the Tac3 
or Tacr3 gene (which encodes NKB or NK3R, respectively) causes a severe gonadotropin deficiency 
in humans.18 Thus, the NKB receptor(s) represents a potential pharmaceutical target to regulate 
pulsatile GnRH secretion. 
NKB, an endogenous NK3R agonist, belongs to the tachykinin peptide family, which shares a 
common C-terminal sequence, -Phe-Xaa-Gly-Leu-Met-NH2.19-21 NKB acts as a neurotransmitter to 
regulate the release of GnRH and dopamine in CNS.22-24 NKB also induces contraction of the portal 
vein, venoconstriction of the mesenteric bed and an increase in the heart rate in the periphery.25-27 
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Substance P (SP) and neurokinin A (NKA) are also known as mammalian tachykinins that show 
preferable binding to NK1R and NK2R, respectively. The receptor selectivity of these endogenous 
tachykinins is modest. There have also been several selective tachykinin receptor ligands reported, 
such as [Pro9]-SP, [Pro10]-SP and [Sar9, Met(O2)11]-SP for NK1R20,21 or [-Ala8]-NKA(4-10) and 
[Nle10]-NKA(4-10) for NK2R.28,29 [MePhe7]-NKB (1a) and senktide, [succinyl-(Asp6 
MePhe8)-SP(6-11)], were also reported to be NK3R-selective agonistic peptides.30,31 Although these 
peptides were apparently designed to investigate the function of tachykinins and the cognate 
receptors,28-31 the essential structural requirements for further potent and selective tachykinin 
receptor ligands have never been fully explored. In this article, we report a structure-activity 
relationship (SAR) of naturally occurring vertebrate/invertebrate tachykinin peptides and 
[MePhe7]-NKB. 
 
2. Results and discussion 
2.1. Synthesis of tachykinin analog peptides 
All peptide chains were constructed by standard Fmoc-based solid-phase peptide synthesis 
(Fmoc-SPPS) on Rink-amide resin. Final deprotection and cleavage from the resin with the cocktail 
[TFA/thioanisole/m-cresol/1,2-ethanedithiol/H2O (80:5:5:5:5)], followed by RP-HPLC purification 
afforded the expected peptides as TFA salts. All peptides were identified with ESI-MS or 
MALDI-TOF-MS and the purity was more than 98% by analytical HPLC. 
 
2.2. Structure-activity relationships of naturally occurring tachykinins and the derivatives 
Initially, we investigated the biological activities of vertebrate and invertebrate tachykinins (Table 
1). The biological activities were evaluated by competitive binding assays using [125I]-BH-SP for 
NK1R, [125I]-NKA for NK2R and ([125I]His3,MePhe7)-NKB for NK3R. We also assessed the NK3R 
agonistic activity by monitoring the intracellular Ca2+ flux induced by NK3R activation.32 All 
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naturally occurring tachykinins showed moderate to weak receptor binding to NK3R. Among the 
eight natural peptides 2a-9a, PG-KII 2a showed slightly higher NK3R agonistic activity [EC50(2a) = 
0.079 nM], whereas it bound to NK3R with more than 10-fold less potency when compared with that 
of [MePhe7]-NKB 1a [IC50(2a) = 53 nM]. Uperolein 4a, eledoisin 5a and kassinin 6a also exerted 
similarly potent NK3R agonistic effects [EC50(4a) = 0.12 nM; EC50(5a) = 0.22 nM; EC50(6a) = 0.21 
nM]. However, these peptides also showed potent binding to NK1R and NK2R at 10 M.  
It was reported that the substitution of the amino acid at position 733 in tachykinins [Phe7 in NKB 
or Phe8 in [pGlu6]-SP(6-11)] with MePhe improved NK3R binding and selectivity.30,31 At this 
position, naturally occurring tachykinin peptides contain various amino acids.21 Alternatively, 
Severini et al. suggested that two acidic amino acids at positions 4 and 5 are responsible for the high 
NK3R selectivity.21 An NK3R-selective agonist, senktide, also contains Asp at this position31 On the 
basis of these previous investigations, we designed several analog peptides of vertebrate and 
invertebrate tachykinins with Asp and MePhe substitutions at positions 5 and 7, respectively. 
All tachykinin derivatives 3b-9b showed more potent binding affinity and agonistic activity to 
NK3R compared with the parent peptides 2a-9a (Table 1). Peptide 3b showed more potent NK3R 
binding affinity than PG-KII 2a and PG-SP1 3a [IC50(3b) = 19 nM], whereas the NK3R agonistic 
activity was similar to that of 2a [EC50(3b) = 0.083 nM]. Peptide 4b also exhibited a similar NK3R 
agonistic activity of uperolein 4a [EC50(4b) = 0.13 nM]. Similarly potent bioactivities of an eledoisin 
derivative 5b to those of 3b and 4b were observed [EC50(5b) = 0.090 nM]. Peptide 6b showed 
3-times higher binding affinity and agonistic activity than kassinin 6a [IC50(6b) = 110 nM; EC50(6b) 
= 0.085 nM] for NK3R. No binding of peptides 3b-7b to NK1R and NK2R were observed, 
indicating that these peptides are NK3R-selective. Peptides 7b and 8b showed much more potent 
binding affinity and agonistic activity than the corresponding naturally occurring sialokinin II 7a and 
physalaemin 8a [IC50(7b) = 81 nM; EC50(7b) = 0.11 nM; IC50(8b) = 54 nM; EC50(8b) = 0.15 nM]. 
The agonistic activity of 7b was comparable to [MePhe7]-NKB 1a. The NK3R binding of peptide 9b 
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was significantly improved over bufokinin 9a [IC50(9b) = 31 nM], whereas a small improvement of 
the agonistic activity was observed [EC50(9b) = 5.04 nM]. Peptides 8b and 9b remained moderate 
NK1R binders.34 As such, Asp5 and MePhe7 are important for NK3R selective binding and agonistic 
activities. In addition, the receptor binding and agonistic activity of Asp5/MePhe7-substituted 
peptides towards NK3R is correlated. Although the contribution of these two residues and the 
C-terminal consensus sequence to the biological activities seems to be dominant, significantly 
different bioactivities among peptides 3b-9b suggest that the N-terminal region is also playing a role 
in defining receptor binding and activation. For example, Lys0 and Arg2 in less potent peptides (9b) 
are unfavorable for NK3R agonistic activity.  
To understand the optimization rationale by Asp and MePhe substitutions for receptor binding, 
selectivity and NK3R agonistic activity, we designed the analogs of eledoisin 5a and kassinin 6a, in 
which each residue at position 5 or 7 was substituted (Table 2). Asp substitution at position 5 in both 
peptides 5a and 6a led to slightly increased receptor binding to NK3R [IC50(5c) = 35 nM; IC50(6c) = 
89 nM]. MePhe substitution at position 7 of 5a and 6a also improved binding affinity for NK3R 
[IC50(5d) = 7.9 nM; IC50(6d) = 13 nM]. Comparing these substitutions, MePhe at position 7 
contributed more significantly to receptor binding. Dual substitutions led to the most potent binding 
to NK3R in eledoisin 5a, whereas the single substitution with MePhe at position 7 resulted in highest 
binding of kassinin 6a. In terms of NK3R agonistic activity, single Asp substitution in eledoisin 5a 
or MePhe substitution in kassinin 6a led to an increase in bioactivity [EC50(5c) = 0.0054 nM; 
EC50(6d) = 0.038 nM]. The potency of peptides 5c and 6d exceeded those of peptides 5b and 6b. Of 
note, NK1R and NK2R binding remained for peptides 5c,d and 6c,d with single Asp or MePhe 
substitutions at 10 M, whereas peptides 5b and 6b did not bind to these receptors. Thus, dual 
Asp/MePhe substitutions provided the desired biological properties with high potency and selectivity 




2.3. Structure-activity relationship study of position 5 in [MePhe7]-NKB 
On the basis of the favorable effects of Asp/MePhe substitutions at positions 5 and 7 for selective 
NK3R agonists, we next designed [MePhe7]-NKB analogs 1b-s to optimize the Phe5 position in 
[MePhe7]-NKB 1a (Table 3). Initially, we evaluated the binding affinity of the derivatives for NK3R. 
The substitution of Phe5 with Arg, Tyr, Trp, Val, Ser or Met resulted in a slight increase in NK3R 
binding (1d, 1g, 1h, 1i, 1o, 1q; IC50 = 1.53.6 nM), whereas the other derivatives showed lower 
binding to NK3R. For example, Asp- or Pro-substituted derivatives showed more than 10-times 
lower binding affinity than the parent [MePhe7]-NKB 1a [IC50(1b) = 38 nM; IC50(1r) = 45 nM]. The 
NK3R agonistic activity was largely similar among the derivatives except for the Trp-substituted 
peptide 1h [EC50(1h) = 0.28 nM]. Peptides 1f and 1l showed 45-times higher agonistic activities 
than that of [MePhe7]-NKB 1a [EC50(1f) = 0.017 nM; EC50(1l) = 0.012 nM]. Moderate correlations 
were observed between the binding affinity and agonistic activity for NK3R, suggesting that the 
amino acid at this position is not a critical factor in determining the biological activity for NK3R.  
We also assessed the binding affinity of the peptides 1a-s to NK1R and NK2R to evaluate the 
receptor selectivity. Peptides 1d, 1e and 1n with a substitution with Arg, Lys and Gln, respectively, 
at position 5 exhibited moderate NK1R binding, whereas the other peptides did not bind to NK1R at 
10 M. In contrast, moderate to low NK2R binding was observed for peptides 1d-1s, except for two 
peptides 1b and 1c that had substitutions with acidic amino acids (Asp or Glu). These observations 
suggest that the negative charge at this position is unfavorable for NK2R binding, and that the 
electrostatic property at this position is more important for an NK3R selective agonist. As such, the 
negatively charged amino acid at position 5 contributes to the receptor selectivity, rather than binding 




In this study, we investigated the structure-activity relationships of naturally occurring tachykinins 
and an NK3R agonist, [MePhe7]-NKB. Among the natural peptide derivatives evaluated, peptides 1b 
and 1c showed NK3R-selective agonistic activity. The SAR study of eledoisin and kassinin 
demonstrated that both Asp and MePhe at positions 5 and 7 contribute to the potent receptor binding 
to NK3R and high NK3R-selectivity. It was also revealed that in the optimization study of Phe5 in 
[MePhe7]-NKB, an acidic amino acid such as Asp and Glu improved the NK3R-selectivity. These 
structure-activity relationship data may facilitate the development of novel NK3R-selective peptide 
ligands as therapeutic agents that induce pulsatile GnRH secretion. 
 
4. Experimental Section  
4.1. Peptide synthesis 
The protected linear peptides were constructed by Fmoc-based solid-phase synthesis on 
Rink-Amide resin (0.66 mmol/g, 45.5 mg, 0.025 mmol). Fmoc-protected amino acids (0.075 mmol) 
were coupled by using N,N'-diisopropylcarbodiimide (DIC, 11.6 μL, 0.075 mmol) and HOBt·H2O 
(11.5 mg, 0.075 mmol) in DMF. Coupling of amino acid to N-methylamino acid was carried out with 
HATU (27.6 mg, 0.73 mmol) and (i-Pr)2NEt (13.0 μL, 0.75 mmol). Completion of each coupling 
reaction was ascertained using the Kaiser ninhydrin test. The Fmoc-protecting group was removed 
by treating the resin with 20% piperidine in DMF. The resulting protected peptide resin was treated 
with TFA/thioanisole/m-cresol/1,2-ethanedithiol/H2O (5 mL; 80:5:5:5:5) at room temperature for 2 h. 
After removal of the resin by filtration, the filtrate was poured into ice-cold dry Et2O (40 mL). The 
resulting powder was collected by centrifugation and then washed three times with ice-cold dry Et2O 
(3  40 mL). The crude product was purified by HPLC on a Cosmosil 5C18-ARII preparative 
column (Nacalai Tesque, 20  250 mm). All peptides were characterized by ESI-MS or 
MALDI-TOF-MS and the purity was calculated as >98% by HPLC on a Cosmosil 5C18-ARII 
analytical column (Nacalai Tesque, 4.6  250 mm). 
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4.2. Evaluation of the binding affinity of tachykinin peptides to NK1R, NK2R and NK3R. 
The experiment was performed using membranes from NK1R-, NK2R- or NK3R-expressing CHO 
cells. For ligand binding, membranes were incubated with 50 μL of increasing concentrations of the 
peptide, 25 μL of radio-active ligand [[125I]-BH-SP for NK1R, [125I]-NKA for NK2R, and ([125I]His3, 
MePhe7)-NKB for NK3R, respectively, 0.4 nM each, Perkin-Elmer Life Sciences] and 25 μL of the 
membrane solution in assay buffer [50 mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM CaCl2, 0.1% 
BSA]. The reaction mixtures were filtered through GF/B filters pretreated with 0.3% 
polyethyleneimine. The filters were washed with [50 mM HEPES (pH 7.4), 500 mM NaCl, 0.1% 
BSA], dried at 55 °C, and then subjected to γ-counting. 
 
4.3. Evaluation of the NK3R agonistic activity 
The NK3R agonistic activity of each peptide was evaluated by the [Ca2+]i flux assay. NK3R 
expressing CHO-K1 cells (4.0  104 cells/50 L/well) were inoculated in 10% FBS/Ham’s F-12 onto 
a 96-well black clear-bottom plate (Greiner), followed by incubation at 37 °C overnight in 5% CO2. 
After the medium was removed, 100 L of the pigment mixture (Calcium 4 assay kit, Molecular 
Devices) was dispensed into each well of the plate, followed by incubation at 37 °C for 1 h. A total 
of 10 mM peptide in DMSO was diluted with HANKS/HEPES containing 2.5 mM probenecid and 
the dilution was transferred to a 96-well sample plate (V-Bottom plate, Coster). The cell and sample 
plates were set in a FlexStation (Molecular Devices) and 25 L of the sample solution was 
automatically transferred to the cell plate.  
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a IC50 values are the concentrations for 50% inhibition of 0.1 nM of ([
125I]His 3, MePhe7)-NKB binding to NK3R (n = 3). The IC50 value of NKB was 76 nM in this assay. b
EC50 values are the concentrations for 50% induction of Ca
2+
influx in NK3R expressing CHO cell (n = 3). The EC50 value of NKB was 0.034 nM in this assay.
c
Binding
inhibition (%)  was calculated by the binding inhibition assay using a radioactive ligand (0.1 nM) and each peptide (10 M). 100% binding inhibition was calculated based on 
the background signals, which were obtained by measurement  of the wells without receptor membrane.
1 2 3 4 5 6 7 8 9 100-1
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Table 3. Structure-activity relationships of Phe5-substituted [MePhe7]-NKB analogs. 
[MePhe7]-NKB H‐Asp‐Met‐His‐Asp‐Xaa‐Phe‐MePhe‐Gly‐Leu‐Met‐NH2 
Peptide Xaa IC50 (n)a EC50 (nM)b Binding Inhibition (%)c 
NK1R NK2R 
[MePhe7]-NKBd (1a) Phe 3.8 0.070 < 10 57
1b Asp 38 0.040 < 10 < 10
1c Glu 7.5 0.024 < 10 < 10
1d Arg 2.5 0.080 60 62
1e Lys 11 0.026 40 35
1f His 5.9 0.017 < 10 47
1g Tyr 1.5 0.072 < 10 51
1h Trp 1.8 0.28 < 10 79
1i Val 1.5 0.065 < 10 29
1j Leu 6.9 0.051 < 10 29
1k Ile 4.0 0.060 < 10 35
1l Ala 4.4 0.012 < 10 33
1m Asn 18 0.036 < 10 10
1n Gln 4.6 0.043 24 21
1o Ser 3.6 0.040 < 10 31
1p Thr 4.3 0.046 < 10 19
1q Met 1.7 0.032 < 10 41
1r Pro 45 0.041 < 10 38
1s Gly 13 0.036 < 10 22
a IC50 values are the concentrations for 50% inhibition of ([125I]His3, MePhe7)-NKB binding (0.1 
nM) to NK3R (n = 3).  
b EC50 values are the concentrations for 50% induction of Ca2+ influx in NK3R expressing CHO 
cells (n = 3). 
c Binding inhibition (%) was calculated by the binding inhibition assay using a radioactive ligand 
(0.1 nM) and each peptide (10 M). 100% binding inhibition was calculated based on the 
background signals, which were obtained by measurement of the wells without receptor membrane. 
d [MePhe7]-NKB: H-Asp-His-Met-Asp-Xaa-Phe-MePhe-Gly-Leu-Met-NH2.  
 
 
